Also, these limitations mean that many women with early stage ovarian cancer will receive a false negative from CA-125 testing and not get further treatment for their condition.
此外，这些限制意味着，许多早期卵巢癌的妇女将收到来自CA-125检测假阴性，并没有得到自己的病情进一步治疗。